Everything below concerns clinical endpoint. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-07. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
3/8 S8 + 6 OH− → 2 S2− + SO2−3 + 3 H2O Adding back 6 Ca2+ cations from hydrated lime for the sake of electroneutrality, one obtains the overall reaction. This last reaction is consistent with the overall lime sulfur reaction mentioned in the USDA document. However, it does not account for all the details, such as the production of thiosulfate and sulfate among the end products of the reaction. Nevertheless, it is a good first-order approximation, and it usefully highlights the overall lime sulfur reaction scheme because the chemistry of reduced or partially oxidized forms of sulfur is particularly complex, and all the intermediate steps or involved mechanisms are hard to unravel. Moreover, once exposed to atmospheric oxygen and microbial activity, the lime sulfur system will undergo a rapid oxidation, and its different products will continue to evolve and eventually enter the natural sulfur cycle. The presence of thiosulfate in the lime sulfur reaction can be accounted for by the reaction between sulfite and elemental sulfur (or with sulfide and polysulfides), and that of sulfate by the complete oxidation of sulfite or thiosulfate, following a more complex reaction scheme. More information on calcium thiosulfate production is described in a patent by Hajjatie et al. (2006). Hajjatie et al. (2006) expressed the lime sulfur reaction in various ways depending on the degree of polymerization of calcium polysulfides, but the following reaction is probably the simplest of their series:
==== Federal government ==== All of the food recalls executed by companies in the United States and Canada were voluntary, i.e. not mandated by any government agency. In the United States, prior to the recall, the Food and Drug Administration did not keep pet foods under the same level of protection and safety ensurance as food intended for human consumption. According to the FDA, the FDA's "regulation of pet food is similar to that for other animal feeds. The Federal Food, Drug, and Cosmetic Act (FFDCA) requires that pet foods, like human foods, be pure and wholesome, safe to eat, produced under sanitary conditions, contain no harmful substances, and be truthfully labeled." However, "there is no requirement that pet food products have premarket approval by FDA." Once the recall was announced, the Food and Drug Administration immediately began to mobilize resources to assist in the investigation. The FDA has dedicated each of its 20 district offices and three field laboratories to the investigation and more than "400 employees are involved in sample pet food collection, monitoring of recall effectiveness, and preparing consumer complaint reports." The FDA has activated its Emergency Operations Center, making sure the information on the poisoning gets to scientists and inspection teams.
He also served as a member of the executive committee of the American Society for Testing and Materials (A.S.T.M.) Committee E-19 on Chromatography (1966–1973); as a foreign member of the executive committee of the (British) Chromatographic Society (1992–1997); and as an executive committee member of the Chromatography Subdivision of the Division of Analytical Chemistry of the American Chemical Society (A.C.S.).
Metallic zinc was isolated in India by 1300 AD. Before it was isolated in Europe, it was imported from India in about AD 1600. Postlewayt's Universal Dictionary, a contemporary source giving technological information in Europe, did not mention zinc before 1751 but the element was studied before then. Flemish metallurgist and alchemist P. M. de Respour reported that he had extracted metallic zinc from zinc oxide in 1668. By the start of the 18th century, Étienne François Geoffroy described how zinc oxide condenses as yellow crystals on bars of iron placed above zinc ore that is being smelted. In Britain, John Lane is said to have carried out experiments to smelt zinc, probably at Landore, prior to his bankruptcy in 1726. In 1738 in Great Britain, William Champion patented a process to extract zinc from calamine in a vertical retort-style smelter. His technique resembled that used at Zawar zinc mines in Rajasthan, but no evidence suggests he visited the Orient. Champion's process was used through 1851. German chemist Andreas Marggraf normally gets credit for isolating pure metallic zinc in the West, even though Swedish chemist Anton von Swab had distilled zinc from calamine four years previously. In his 1746 experiment, Marggraf heated a mixture of calamine and charcoal in a closed vessel without copper to obtain a metal. This procedure became commercially practical by 1752.
=== Pathophysiological models === Clinical professionals continue to debate the causes of spontaneous upper airway blockage. The areas of thought are divided mostly into three medical groups. Some pulmonologists and neurologists believe the risk factors to be:
Sources: en.wikipedia.org
Nuclear DNA has two copies per cell (except for sperm and egg cells), one copy being inherited from the father and the other from the mother. Mitochondrial DNA, however, is inherited from the mother only (with some exceptions) and each mitochondrion typically contains between 2 and 10 mtDNA copies. During cell division the mitochondria segregate randomly between the two new cells. Those mitochondria make more copies, normally reaching 500 mitochondria per cell. As mtDNA is copied when mitochondria proliferate, they can accumulate random mutations, a phenomenon called heteroplasmy. If only a few of the mtDNA copies inherited from the mother are defective, mitochondrial division may cause most of the defective copies to end up in just one of the new mitochondria (for more detailed inheritance patterns, see human mitochondrial genetics). Mitochondrial disease may become clinically apparent once the number of affected mitochondria reaches a certain level; this phenomenon is called "threshold expression". Mitochondria possess many of the same DNA repair pathways as nuclei do—but not all of them; therefore, mutations occur more frequently in mitochondrial DNA than in nuclear DNA (see Mutation rate). This means that mitochondrial DNA disorders may occur spontaneously and relatively often. Defects in enzymes that control mitochondrial DNA replication (all of which are encoded for by genes in the nuclear DNA) may also cause mitochondrial DNA mutations. Most mitochondrial function and biogenesis is controlled by nuclear DNA.
Thrombocytopenia, i.e. can be associated with heparin-induced thrombocytopenia (0.5-5.0% of persons treated for at least five days) Elevations in serum aminotransferases: 5.9%-6.1% In people undergoing abdominal or colorectal surgery: Bleeding, anemia, ecchymosis: ≥ 2% In persons undergoing hip or knee replacement: Fever, nausea, anemia, edema, peripheral edema: ≥ 2% In persons with severely restricted mobility during acute illness: Dyspnea, thrombocytopenia, confusion, diarrhea, nausea: ≥ 2% In people being treated for deep vein thrombosis: Injection site hemorrhage, injection site pain, hematuria: ≥ 2% Frequency under investigation
=== Ammunition === Most military use of depleted uranium has been as 30 mm ordnance, primarily the 30 mm PGU-14/B armor-piercing incendiary round from the GAU-8 Avenger cannon of the A-10 Thunderbolt II used by the United States Air Force. 25 mm DU rounds have been used in the M242 gun mounted on the U.S. Army's Bradley Fighting Vehicle and the Marine Corps's LAV-25. The U.S. Marine Corps uses DU in the 25 mm PGU-20 round fired by the GAU-12 Equalizer cannon of the AV-8B Harrier, and in the 20 mm M197 gun mounted on AH-1 Cobra helicopter gunships. The United States Navy's Phalanx CIWS's M61 Vulcan Gatling gun used 20 mm armor-piercing penetrator rounds with discarding plastic sabots and a core made using depleted uranium, however they later changed to using tungsten penetrators.
==== Binge eating disorder ==== Binge eating disorder (BED) is characterized by recurrent and persistent episodes of compulsive binge eating. These episodes are often accompanied by marked distress and a feeling of loss of control over eating. The pathophysiology of BED is not fully understood, but it is believed to involve dysfunctional dopaminergic reward circuitry along the cortico-striatal-thalamic-cortical loop. As of July 2024, lisdexamfetamine is the only USFDA- and TGA-approved pharmacotherapy for BED. Evidence suggests that lisdexamfetamine's treatment efficacy in BED is underpinned at least in part by a psychopathological overlap between BED and ADHD, with the latter conceptualized as a cognitive control disorder that also benefits from treatment with lisdexamfetamine. Lisdexamfetamine's therapeutic effects for BED primarily involve direct action in the central nervous system after conversion to its pharmacologically active metabolite, dextroamphetamine. Dextroamphetamine increases dopaminergic and noradrenergic neurotransmission in prefrontal cortex, a region of the brain that regulates cognitive control of behavior. Similar to its therapeutic effect in ADHD, dextroamphetamine enhances cognitive control and may reduce impulsivity in patients with BED by enhancing the cognitive processes responsible for overriding prepotent feeding responses that precede binge eating episodes.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.